Exploring the Role of ADCs in Brain Metastases and Primary Brain Tumors: Insight and Future Directions.

Publisher: MDPI Country of Publication: Switzerland NLM ID: 101526829 Publication Model: Electronic Cited Medium: Print ISSN: 2072-6694 (Print) Linking ISSN: 20726694 NLM ISO Abbreviation: Cancers (Basel) Subsets: PubMed not MEDLINE

Original Publication: Basel, Switzerland : MDPI

Primary and secondary brain tumors have always been a challenge due to their high morbidity and poor prognosis. The incidence of brain metastasis is also increasing with the advent of effective new treatments. Traditional systemic treatments have historically had limited success, partly due to poor central nervous system (CNS) penetration. However, the advent in recent decades of new therapies that have shown high encephalic response rates are challenging this paradigm. ADCs represent a new class of compounds revolutionizing cancer treatment with high systemic response rates and lower toxicities. The continuing evolution of ADCs has shown that certain structural features such as payload, linker, and drug-to-antibody ratio (DAR) are essential in determining their efficacy at the encephalic level, and some ADCs have started to exhibit promising efficacy in treating primary and secondary brain tumors. Unfortunately, most patients with untreated encephalic metastases are excluded from clinical trials, with data primarily from retrospective studies or post hoc analyses. This review describes the early signs of ADC efficacy in brain tumors, the role of complementary treatments like radiation therapy, and critical points to improve ADC efficacy in brain malignancies.

Proc Natl Acad Sci U S A. 2009 Feb 24;106(8):2712-6. (PMID: 19196966)
Front Immunol. 2024 Jan 04;14:1332057. (PMID: 38239350)
Cell Rep. 2022 May 24;39(8):110839. (PMID: 35613589)
Cancer. 2008 Oct 1;113(7 Suppl):1953-68. (PMID: 18798534)
Neuro Oncol. 2023 Jan 5;25(1):157-166. (PMID: 35639825)
J Histochem Cytochem. 2011 Jul;59(7):701-10. (PMID: 21551320)
Oncologist. 2023 Oct 3;28(10):e859-e866. (PMID: 37218076)
Lancet Oncol. 2023 Apr;24(4):e161-e171. (PMID: 36990614)
Nat Commun. 2022 Dec 5;13(1):7495. (PMID: 36470901)
Pharmaceutics. 2025 Feb 14;17(2):. (PMID: 40006625)
Front Oncol. 2023 Jun 29;13:1151090. (PMID: 37456256)
Neuro Oncol. 2022 Mar 12;24(3):429-441. (PMID: 34608482)
Neuro Oncol. 2020 May 15;22(5):684-693. (PMID: 31747009)
Org Lett. 2024 Jul 12;26(27):5597-5601. (PMID: 38639400)
Nat Med. 2024 Dec;30(12):3717-3727. (PMID: 39271844)
Cancers (Basel). 2021 May 15;13(10):. (PMID: 34063335)
Nat Rev Dis Primers. 2019 Jan 17;5(1):5. (PMID: 30655533)
Neuro Oncol. 2023 Feb 14;25(2):339-350. (PMID: 35849035)
Med. 2025 Jan 10;6(1):100502. (PMID: 39265579)
JCO Precis Oncol. 2024 Mar;8:e2300487. (PMID: 38547418)
Cancer. 1994 Aug 1;74(3 Suppl):1006-12. (PMID: 7913661)
JAMA Oncol. 2023 Feb 1;9(2):197-205. (PMID: 36454580)
Nat Rev Clin Oncol. 2023 Jun;20(6):372-389. (PMID: 37085569)
Nat Med. 2023 Aug;29(8):2110-2120. (PMID: 37488289)
Clin Cancer Res. 2024 Aug 1;30(15):3287-3297. (PMID: 38743766)
NPJ Breast Cancer. 2024 Apr 25;10(1):33. (PMID: 38664404)
Nat Med. 2002 May;8(5):459-65. (PMID: 11984589)
Cancers (Basel). 2020 Nov 11;12(11):. (PMID: 33187148)
Am Soc Clin Oncol Educ Book. 2022 Apr;42:1-9. (PMID: 35427188)
Neuro Oncol. 2018 May 18;20(6):838-847. (PMID: 29077941)
Nat Rev Neurol. 2017 Jan;13(1):52-64. (PMID: 27982041)
J Clin Oncol. 2020 Nov 10;38(32):3773-3784. (PMID: 32931399)
Signal Transduct Target Ther. 2022 Mar 22;7(1):93. (PMID: 35318309)
Clin Cancer Res. 2016 Oct 15;22(20):5097-5108. (PMID: 27026201)
Neuro Oncol. 2021 Jun 1;23(6):894-904. (PMID: 33367836)
Oncogene. 2018 Jan 4;37(1):52-62. (PMID: 28869599)
J Clin Oncol. 2018 Aug 28;:JCO2018783118. (PMID: 30153097)
Nat Rev Cancer. 2012 Jan 24;12(2):89-103. (PMID: 22270953)
Neuro Oncol. 2021 Dec 1;23(12):2042-2053. (PMID: 34050676)
BMC Cancer. 2018 Jan 25;18(1):97. (PMID: 29370839)
ESMO Open. 2024 Sep;9(9):103699. (PMID: 39255534)
Neuro Oncol. 2010 Aug;12(8):871-81. (PMID: 20511192)
Cancer Chemother Pharmacol. 2017 Dec;80(6):1209-1217. (PMID: 29075855)
Nat Commun. 2024 Aug 7;15(1):6707. (PMID: 39112464)
Neuro Oncol. 2014 Jul;16(7):1006-9. (PMID: 24497407)
Neuropharmacology. 2017 Jul 1;120:38-55. (PMID: 26972827)
Nat Med. 2024 Aug;30(8):2208-2215. (PMID: 38825627)
Crit Rev Oncol Hematol. 2024 Feb;194:104239. (PMID: 38128629)
Ann Oncol. 2020 Oct;31(10):1350-1358. (PMID: 32634611)
Lancet Oncol. 2014 Jun;15(7):689-99. (PMID: 24793816)
Ecancermedicalscience. 2015 Oct 22;9:586. (PMID: 26557884)
Bioconjug Chem. 2021 Apr 21;32(4):746-754. (PMID: 33689309)
Cancers (Basel). 2023 Jan 24;15(3):. (PMID: 36765668)
Biophys J. 1963 Jan;3:11-33. (PMID: 13980635)
BMC Cancer. 2016 Jul 04;16:391. (PMID: 27377061)
NPJ Precis Oncol. 2023 Jan 11;7(1):5. (PMID: 36631624)
J Thorac Oncol. 2023 Jun;18(6):769-779. (PMID: 36738928)
J Clin Oncol. 2024 Sep 1;42(25):3000-3011. (PMID: 38843488)
Nat Med. 2022 Sep;28(9):1840-1847. (PMID: 35941372)
Mol Cancer Ther. 2019 Nov;18(11):1926-1936. (PMID: 31649014)
Neuro Oncol. 2019 Jan 1;21(1):106-114. (PMID: 29982805)
J Clin Oncol. 2020 Jun 10;38(17):1887-1896. (PMID: 32058843)
Nat Rev Cancer. 2020 Jan;20(1):26-41. (PMID: 31601988)
Cancer Res. 2012 Jun 15;72(12):2924-30. (PMID: 22659454)
Clin Cancer Res. 2024 Feb 16;30(4):779-785. (PMID: 38048058)
Cancers (Basel). 2022 Jun 28;14(13):. (PMID: 35804940)
Neuro Oncol. 2017 Jul 01;19(7):965-975. (PMID: 28039367)
Oncotarget. 2015 Mar 10;6(7):5465-74. (PMID: 25760072)
Clin Transl Oncol. 2023 May;25(5):1218-1241. (PMID: 36897508)
Medicine (Baltimore). 2022 Nov 25;101(47):e32042. (PMID: 36451503)
JAMA Oncol. 2023 Dec 1;9(12):1729-1733. (PMID: 37883079)
J Clin Oncol. 2024 Mar 1;42(7):808-820. (PMID: 38042525)
N Engl J Med. 2019 Feb 14;380(7):617-628. (PMID: 30516102)
Neurooncol Pract. 2020 Jul 16;8(1):18-30. (PMID: 33664966)
Biomedicines. 2021 Jul 23;9(8):. (PMID: 34440076)
Lancet Oncol. 2013 Mar;14(3):244-8. (PMID: 23414588)
Neuro Oncol. 2022 Oct 5;24(Suppl 5):v1-v95. (PMID: 36196752)
Front Oncol. 2022 May 24;12:857622. (PMID: 35686091)
J Med Chem. 2024 Oct 24;67(20):18124-18138. (PMID: 39410752)
Cancer Radiother. 2021 Apr;25(2):126-134. (PMID: 33431297)
Oncotarget. 2017 Apr 25;8(17):28725-28735. (PMID: 28404926)
J Thorac Oncol. 2021 Nov;16(11):1883-1892. (PMID: 34265431)
Ann Oncol. 2015 Jan;26(1):113-119. (PMID: 25355722)
Lancet Oncol. 2017 Jun;18(6):732-742. (PMID: 28526536)
J Clin Oncol. 2004 Jul 15;22(14):2865-72. (PMID: 15254054)
Nat Commun. 2016 Oct 04;7:13019. (PMID: 27698471)
J Thorac Oncol. 2023 Dec;18(12):1703-1713. (PMID: 37392903)
Int J Mol Sci. 2022 Jun 09;23(12):. (PMID: 35742920)
J Pharm Sci. 2021 Dec;110(12):3776-3785. (PMID: 34363839)
Front Mol Biosci. 2022 Mar 15;9:834651. (PMID: 35372498)
J Clin Oncol. 2024 Oct 10;42(29):3400-3409. (PMID: 38819031)
N Engl J Med. 2020 Feb 13;382(7):597-609. (PMID: 31825569)
Toxins (Basel). 2010 Nov;2(11):2645-62. (PMID: 22069569)
World Neurosurg. 2018 Mar;111:109-114. (PMID: 29274446)
Cancer Sci. 2021 Dec;112(12):5020-5033. (PMID: 34609773)
Oncogene. 2018 Mar;37(12):1561-1575. (PMID: 29321659)
J Exp Clin Cancer Res. 2022 Oct 21;41(1):310. (PMID: 36271429)
J Clin Oncol. 2023 Oct 1;41(28):4478-4485. (PMID: 37603816)
Neuro Oncol. 2008 Jun;10(3):320-9. (PMID: 18403491)
N Engl J Med. 2021 Apr 22;384(16):1529-1541. (PMID: 33882206)
Cancers (Basel). 2021 Jun 03;13(11):. (PMID: 34204877)
Cancer Discov. 2022 Dec 2;12(12):2754-2762. (PMID: 36255231)
Cell Death Discov. 2024 Feb 15;10(1):79. (PMID: 38360912)
Br J Cancer. 2017 Dec 5;117(12):1736-1742. (PMID: 29065110)
J Neurooncol. 2019 Aug;144(1):205-210. (PMID: 31273577)
Neuro Oncol. 2023 Jun 2;25(6):1085-1097. (PMID: 36640127)
Eur J Cancer. 2020 Jun;132:187-198. (PMID: 32380429)
J Cell Biol. 1997 Apr 7;137(1):211-20. (PMID: 9105049)
Oncol Rep. 2019 Feb;41(2):753-764. (PMID: 30431125)
J Membr Biol. 2014 Apr;247(4):291-307. (PMID: 24573305)

Keywords: antibody–drug conjugates (ADCs); breast cancer; lung cancer; neuro-oncology; radiotherapy; targeted therapies

Date Created: 20250514 Latest Revision: 20250516

20250519

PMC12072133

10.3390/cancers17091591

40361515